Zynex, through its subsidiary, Zynex Medical, Inc. (ZMI), designs, manufactures, and markets medical devices designed to treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. ZMI's primary product is the NexWave® device. ZMI distributes complimentary products such as lumbar support, cervical traction, and hot/cold therapy. ZMI designs, manufactures, and markets the NeuroMove product, which is primarily used for stroke, spinal cord and traumatic brain injury rehabilitation. ZMI also designs, manufactures, and markets the InWave product, an in-home electrical stimulation device used to treat female urinary incontinence. The ZYXI stock yearly return is shown above.
The yearly return on the ZYXI stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ZYXI annual return calculation with any dividends reinvested as applicable (on ex-dates).
|